$3.18▴ 0.32%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-320.95MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-56.1%year over year
Weak
Revenue is contracting year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Recursion Pharmaceuticals, Inc. - Class A Common Stock is pre-profit. It is still burning cash while pre-profit. Revenue is contracting year over year.
Key numbers
Valuation
EPS (TTM)$-1.16
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-842.9%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$66.41M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days5 articles
4 bullish0 neutral1 bearish
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
3 Stocks With the Most Upside by the End of 2026
2 Beaten-Down Stocks That Still Aren't Worth BuyingGenerative AI in Drug Discovery: Revolutionizing Pharmaceutical Research and Development
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.